Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)

OBJECTIVE: In the primary analysis of the phase 2b VESTA study, oral fezolinetant reduced frequency and severity of menopausal vasomotor symptoms (VMS) compared with placebo. This secondary analysis evaluates effects of fezolinetant on responder rates and patient-reported outcomes (PROs). METHODS: I...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Menopause
Auteurs principaux: Santoro, Nanette, Waldbaum, Arthur, Lederman, Samuel, Kroll, Robin, Fraser, Graeme L., Lademacher, Christopher, Skillern, Laurence, Young, James, Ramael, Steven
Format: Artigo
Langue:Inglês
Publié: Lippincott Williams & Wilkins 2020
Sujets:
Original Studies
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709922/
https://ncbi.nlm.nih.gov/pubmed/32769757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001621
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires